| answer text |
<p>If someone is detected during bowel screening to have blood in their faeces, then
found to have inflammatory bowel disease (IBD) through follow up tests they are referred
to the symptomatic service for onward management and surveillance. They are then offered
screening every two years along with ongoing monitoring and surveillance, the timeframes
of which are detailed below.</p><p>The National Institute for Health and Care Excellence
(NICE)’s guideline on colorectal cancer prevention was published in March 2011 and
updated in September 2022. It recommends using colonoscopy to check for signs of bowel
cancer in people aged 18 years old and over with ulcerative colitis or Crohn’s disease.
The guidance recommends that follow-up and ongoing colonoscopic surveillance should
be arranged at regular intervals for people with IBD and tubular adenoma as follows:</p><p>-
Low risk: offer colonoscopy at five years;</p><p>- Intermediate risk: offer colonoscopy
at three years; or</p><p>- High risk: offer colonoscopy at one year.</p><p>A copy
of the guidance is attached.</p><p>We expect integrated care boards (ICBs) to have
due regard to relevant NICE guidelines when commissioning services. It is the responsibility
of ICBs to make available appropriate provision to meet the health and care needs
of their local population, in line with these NICE guidelines.</p>
|
|
